This grant is to provide support for the Statistics and Data Management Center (SDMC) of the ECOG- ACRIN Cancer Research Group. The SDMC provides methodologic expertise, leadership, and support for the effective design and conduct of studies and collaborates in the management of NCTN. The Center has a streamlined leadership and organizational structure for its four offices located at the Department of Biostatistics and Computational Biology at the Dana-Farber Cancer Institute (DFCI), the Department of Biostatistics, Center for Statistical Sciences at Brown University, the Frontier Science and Technology Research Foundation (FSTRF), and the American College of Radiology (ACR), under the direction of the Group Statisticians. The primary responsibility for data collection and management belongs to the Data Management Center, with offices in Boston (FSTRF) and Philadelphia (ACR). The primary responsibility for study design, monitoring, and analysis, and for overseeing and coordinating SDMC operations belongs to the Biostatistics Center, with offices in Boston (DFCI) and Providence (Brown University);The prime contact site for grant administration is DFCI.

Public Health Relevance

The primary goals of the SDMC are to provide methodologic expertise, leadership, and support in the design, development, implementation, and analysis of NCTN studies led by ECOG-ACRIN, to provide efficient and timely data collection and management of those studies, and to participate actively in all aspects of the collective management of the NCTN.

National Institute of Health (NIH)
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Mooney, Margaret M
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Dana-Farber Cancer Institute
United States
Zip Code
Ganjoo, Kristen; Hong, Fangxin; Horning, Sandra J et al. (2014) Bevacizumab and cyclosphosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-cell or natural killer cell neoplasms: an Eastern Cooperative Oncology Group study (E2404). Leuk Lymphoma 55:768-72
Dutcher, Janice P; Neuberg, Donna; Atkins, Michael B et al. (2014) Report of a phase I evaluation of dose and schedule of interleukin-1 alpha and cyclophosphamide in patients with advanced tumors: An Eastern Cooperative Oncology Group study (PX990) and review of IL-1-based studies of hematopoietic reconstitution. J Interferon Cytokine Res 34:376-84
Tevaarwerk, Amye J; Wang, Molin; Zhao, Fengmin et al. (2014) Phase III comparison of tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with node-negative, hormone receptor-positive breast cancer (E-3193, INT-0142): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 32:3948-58
Hodi, F Stephen; Lee, Sandra; McDermott, David F et al. (2014) Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial. JAMA 312:1744-53
Kaplan, David; Sun, Zhuoxin; Tallman, Martin S et al. (2014) Prognostic information and biological insights in chronic lymphocytic leukemia by high-resolution immunophenotypic analysis of ZAP70. Cytometry A 85:798-808
Zeidan, Amer M; Lee, Ju-Whei; Prebet, Thomas et al. (2014) Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSS. Br J Haematol 167:62-8
Chung, C H; Lee, J W; Slebos, R J et al. (2014) A 3'-UTR KRAS-variant is associated with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Ann Oncol 25:2230-6
Psyrri, Amanda; Lee, Ju-Whei; Pectasides, Eirini et al. (2014) Prognostic biomarkers in phase II trial of cetuximab-containing induction and chemoradiation in resectable HNSCC: Eastern cooperative oncology group E2303. Clin Cancer Res 20:3023-32
Schneider, B P; Li, L; Shen, F et al. (2014) Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100. Br J Cancer 111:1241-8
Philip, Philip A; Chansky, Kari; LeBlanc, Michael et al. (2014) Historical controls for metastatic pancreatic cancer: benchmarks for planning and analyzing single-arm phase II trials. Clin Cancer Res 20:4176-85

Showing the most recent 10 out of 36 publications